|
Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy. |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Cochlear; Medel |
|
|
Consulting or Advisory Role - Brainlab |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Abbvie; AstraZeneca (I); Bristol-Myers Squibb; Celgene (I); Clovis Oncology; Seagen (I) |
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Alexion Pharmaceuticals; Bristol-Myers Squibb; Merck Serono; Novartis; Pfizer |
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Merck Serono |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck KGaA; Roche; Sanofi; Servier/Pfizer |
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Hexal; Lilly/ImClone; Merck Serono; Merck Sharp & Dohme; Mundipharma; Sanofi |
Research Funding - several companies in coooperation for clincal studies and for preclinical laboratory work (at my institution more than 100 ongoing reserach projects) (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pfizer; Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Novartis |
|
Travel, Accommodations, Expenses - Gilead Sciences; Hexal |